BioStem Technologies, Inc.: PNC FINANCIAL SERVICES GROUP, INC. discloses a stake of more than 5% (Schedule 13G)
Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 5 November 2026, by SEC EDGAR SCHEDULE 13G
30Impact 30 of 100, routine
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
PNC Financial Services Group disclosed a stake exceeding 5% in BioStem Technologies via a Schedule 13G filing with the SEC (accession 0001193125-26-448634). The passive-investment disclosure signals PNC's sizable position in the regenerative-medicine company. The exact share count and percentage were not specified in the filing headline. Investors will watch for further 13G amendments or 13D filings that could indicate a more active stance.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
PNC Financial Services Group, Inc., BioStem Technologies, Inc.